HIV Treatment
Alexander McMeeking, MD
155 West 19th Street, 4th Floor
New York, NY 10011
Phone212.929.2629 Fax212.929.4971
Are You at Risk for HIV?
Take our Quiz

Alexander McMeeking MD FACP

The most comprehensive HIV care and treatment for better living.

Credentials

Name:
Alexander A. McMeeking, M.D., FACP
Address:
Office:
Alexander McMeeking, MD
155 West 19th Street, 4th Floor, New York, NY 10011
Phone212.929.2629 Fax212.929.4971
Marital Status:
Married
Children:
None
Birthplace:
Glasgow, Scotland
Citizenship:
USA
Education:
College:
Farleigh Dickenson University, Rutherford Campus, 9/74 - 5/78 Degree: B.S. 1978
Medical School:
New Jersey Medical School, Newark, NJ, 9/78 - 5/82 Degree: M.D. 1982
St. Luke’s-Roosevelt Hospital Center, New York, NY Internship: 7/82 -6/83 Residency: 7/83 - 6/85
New York University/Bellevue Medical Center, New York, NY Fellow - Infectious Diseases 7/85- 6/87
Honors:
Graduated Summa Cum Laude, Phi Beta Kappa and Phi Omega Epsilon honor societies.
Work Experience
New York University/Bellevue Medical Center, NYC, NY Attending Physician - Infectious Diseases - 7/87 - Present
Director, AIDS and Infectious Disease Clinic – Bellevue Hospital - 7/87 - 6/89
Instructor in Medicine 7/87 - 7/94
Clinical Assistant Professor in Medicine 7/09 - 7/02
Clinical Associate Professor in Medicine 7/02 - Present
License:
New York State: Since 1983
Professional Membership:
Hepatitis Resource Network, 1/1999 - Present
American Medical Association, 1985 - Present
Fellow, American College of Physicians, 1995 - Present
Member, Infectious Diseases Society of America, 1987 - Present
Member, Harvey Society, 1987 - Present
Certifications:
Board Certified in Internal Medicine, September 11, 1985
Board Certified in Infectious Diseases, November 1, 1988
Institutional Administrative Responsibilities:
Director of Clinical Virologic Research, NYU Medical Center, Tisch Hospital, 2002
Pharmacy and Therapeutic Committee, NYU Medical Center, 1989 - Present
Quality Assurance Committee, NYU Medical Center, 1991- Present
Infection Control Committee, NYU Medical Center, 1989 - Present
Subinvestigator, AIDS Clinical Trials Unit, NYU Medical Center, 2005 - Present
Hospital Affiliations:
Tisch Hospital of the NYU Medical Center, New York, NY
Hospital for Joint Diseases, New York, NY
Civic Activities:
Member, Advisory Board of the HIV Arts Network, October 1993 - Present. The HIV Arts Network is a not-for-profit organization supplying information and counseling on HIV to the arts community of New York City. Approximately 100 hours per year.
Editorial Board: The PRN Notebook of the Physicians Research Network, New York, NY
Editorial Board: Clinical Infectious Diseases, 2000 - present
Research Activities:
  1. Therapy of cryptosporidiosis in patients with AIDS using oral Bovine Transfer Factor in a prospective double-blinded study with evaluation of immunologic status pre and post therapy following lymphocyte proliferation assays and T cell helper/suppressor ratios.
  2. Immune stimulation therapy in patients with AIDS using oral Bovine TransferFactor and AZT in prospective double-blinded study.
  3. Principal Investigator at NYU for compassionate use of Fluconalzole in infections.Pfizer Pharmaceuticals, 1988 - 1999.
  4. Co-investigator at NYU for study of Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) in patients with CMV retinitis who develop neutropenia on Gancyclovir, 1991 - 1994.
  5. Co-investigator at NYU for study of oral Gancyclovir for CMV viral retinitis.  Roche Pharmaceuticals, 1991 - 1994.
  6. Principal investigator at NYU for study of oral Gancyclovir as a prophylaxsis against systemic CMV infection in patients with HIV disease, 1992 - 1994.
  7. Co-investigator at NYU of PIXY 321 hematopoietic growth factor for patients with HIV-related pancytopenia, 1994 - 1996.
  8. Co-investigator at NYU for the use of a Polymerase Chain Reaction (PCR) to evaluate bone marrow samples from AIDS patients for acid fast organisms.
  9. Co-investigator at NYU for the use of implant gancyclovir to treat CMV viral in AIDS patients. Roche Pharmaceuticals, 1995 - 1998.
  10. Principle investigator, NYU, 1592 Abacavir Reverse Transcriptase Inhibitor-Phase three study for Glaxo Welcome Company, 6/97 - 6/98.
  11. Principle investigator, NYU for Saquinavir Gel. Cap Protease-Inhibitor for HIV infections, Roche Pharmaceuticals, 5/97 - 6/99.
  12. Co-investigator, NYU, oral gancyclovir prodrug as therapy for CMV retinitisRoche Pharmaceuticals, 3/97 -2001.
  13. Principle investigator, NYU comparing single vs double protease inhibitor therapy in treatment-naive HIV positive patients - Merck Pharmaceuticals, 9/98 - 5/00.
  14. Co-investigator, NYU, pegalated interferon versus standard interferon therapy for Hepatitis C viral infection. Roche Pharmaceuticals, 6/98 - 5/00.
  15. Co-investigator, NYU, pegalated interferon versus standard interferon therapy for co-infected HIV/ Hepatitis C viral infection. - Roche Pharmaceuticals, 2/00 - 9/02.
  16. Investigator, CHORUS Data Base, a prospective observational database of 4,000 HIV positive patients ongoing at four sites in U.S. - Glaxo Welcome 7/97 - 5/2002.
  17. Principle investigator, NYU site. Salvage therapy Hepatitis C treatment failures with pegalated interferon and Thymosin alpha -1.SciClone Pharmaceuticals, 4/03-8/05.
  18. Principle investigator, NYU site. Open label treatment protocol Tipranavir co-administered with Ritonavir in PI-experienced patients with HIV.Phase III trial. Boehringer Ingelheim Company, 5/04 - 11/05.
  19. Subinvestigator ACTG 5186.A Phase II trial of the effects of combination therapy with fish oil supplement and fenofibrate on triglyceride levels in subjects on HAART.September 2004 - Present.
  20. Subinvestigator ACTG 5197.A Double-blind placebo controlled phase II study to evaluate the antiretroviral effect of immunization with the MRK AD5 HIV-1 GAG vaccine in HIV-1 infected individuals.September 2004-present.
  21. Principle Investigator.Multicenter randomized trial of CCR5 antagonist UK-427,857 with optimized background therapy for treatment of antiretroviral-experienced HIV-1 infected subjects.11/05 - Present.
Publications:
  1. McMeeking AA, Codd WJ, Hanna BA.Report of a wound infection caused by Vibrio Parahemolyticus and Vulnificus.Diagnostic Microbiology and Infectious Disease 1986;5:221-223.
  2. Schuster M, Cohn J, McMeeking AA.Disinfection for HTLV III: Halogenated soaps.Journal of the American Medical Association 1986;255:2290-2291.
  3. Cohn J, McMeeking AA, Cohen W, Jacobs J, Holzman R. Response and Survival in Patients Treated for Presumed vs. Proven CNS Toxoplasmosis. (Abstract)III International Conference on AIDS, Washington, D.C., June 1-5, 1987.
  4. McMeeking AA. Chloroquine and Fansidar Prophylaxis - A Reply.(Letter) Journal of Infectious Diseases 1987;155:1351.
  5. McMeeking AA, Holzman R, Desiderio D, Hanna B.Group B Streptococcal osteomyelitis in as adult. New York State Journal of Medicine 1987;87: 466-7.
  6. McMeeking AA, Holzman R.Group G Streptococcal bacteremia and parenteral drug abusers. Journal of Infectious Diseases 1988;157:612.
  7. McMeeking AA, Borkowsky W, Klesius PH, et al.Controlled trial of Bovine Transfer Factor therapy for cryptosporidiosis in AIDS patients. (Abstract 7110) IV International Conference on AIDS, Stockholm, Sweden, June 13-14, 1988.
  8. McMeeking AA, Gonzalez R, Hanna B. Mammary tuberculosis. New York State Journal of Medicine1989; 89: 288-289.
  9. Cohn J, McMeeking AA, Cohen W, Jacobs J, Holzman R.Evalution of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome.American Journal of Medicine1989; 86: 521-527.
  10. Weiss S, Visser E, Rodgers P, McMeeking AA, Schlamm H.Outpatient transfusion therapy for Retrovir-associated anemia.(Absrtact W.B.P. 375) V International Conference on AIDS, Montreal, Canada, June 4-9, 1989.
  11. Cohn J, McMeeking AA, Schlamm H, Vogler M, Allen S, Holzman R. Efficacy of AZT in a Municipal Hospital Clinic. (Abstract W.B.P. 353) V International Conference on AIDS, Montreal, Canada, June 4-9.
  12. Klesius PH, McMeeking AA, Bokowsky W, Bonk S, Holzman R, Lawrence HS. Immunotherapy of Cryptosporidium parvum with Bovine Transfer Factor. IN: Research and Applications of Transfer Factor and DLE. (H. Baolai, W. Ruzhang and Z. Zhaofen, eds.)Xueyan Press, Bejing, China, 1989. pp. 227-254.
  13. McMeeking AA, Schwartz L, Garay S. Don’t Forget AIDS at Any Age. (letter) Journal of the American Geriatric Society 1989; 37:1204-1205.
  14. McMeeking AA, Borkowsky W, Klesius PH, Bonk S, Holzman R, Lawrence, HS. A controlled trial of bovine dialyzable leukocyte extract for Cryptosporidiosis in patients with AIDS. Journal of Infectious Diseases 1990; 161:108-112.
  15. Dietrich DT,Kim MH, McMeeking AA, Rotterdam H. Cytomegalovirus in a patient with Acquired Immunodeficiency Syndrome. American Journal of Gastroenterology1991;86: 904-906.
  16. Poles MA, McMeeking AA, Scholes JV, Dieterich DT. Actinomyces Infection of a Cytomegalovirus Esophageal Ulcer in Two Patients with Acquired Immunodeficiency Syndrome.American Journal of Gastro-enterology1994; 89: 1569-2572.
  17. Goldenberg A, McMeeking AA, Yunzhen C, Garrison L. A Phase I Study of PIXY 321 for HIV Related Pancytopenia(Abstract 3709). American Society of Hematology, Seattle, Washington, December 12-16, 1995.
  18. Gandhi S, McMeeking AA, Friedberg D, Holzman R.Cryptococcal Choroiditis in a Patient with AIDS( Case report and review). Journal ofInfectious Disease 1996; 23: 1193-1194.
  19. Haung PP, McMeeking AA, Stempien MJ, Zagzag D. Cytomizgalovibus Disease Presenting as a Focal Brain Mass: Report of two cases.Journal of Neurosurgery1997;40:1074-1079.
  20. Dipasquali B, McMeeking AA, Tierno PM. IgM and IgG Antibody Titers to Bartonrilla Henselae in HIV Positive and Healthy Individuals in the New York Area (Abstract V24).American Society for Microbiology, Miami Beach, Florida, May 4-8, 1997.
  21. Klein P, McMeeking AA, Goldenberg A.Babesiosis in a Patient with Sickle Cell Anemia. American Journal of Medicine 1997;40:416.
  22. Gorniak RJ, Kramer EL, McMeeking AA, Zagzag D.Thalium-201 Uptake in Cytomegalovirus Encephalitis.Journal of Nuclear Medicine 1997; 38 1386-88.
  23. Dietrich D, Braun J, Mullen M, McMeeking AA.Incidence of Body Habitus Changes in a Cohort of HIV-infected Patients. (Abstract 674).Infectious Disease Society of America.Philadelphia, PA.September, 1998.
  24. Weisz K, Kreiswirth S, McMeeking AA.Erythropoietin Use For Riboviron/Interferon Induced Anemia in Patients With Hepatitis C.(Abstract 325) in Program and Abstracts of the 38th International Conference on Antimicrobial Agents and Chemotherapy.Washington, D.C.1998.
  25. Valentine F, Peiperl L, McMeeking AA, et al. The Occurrence of Opportunistic Infections at Relatively High CD4 Levels is Associated with an Antigen-Specific Absence of Lymphocyte Proliferative Responses. Program and Abstracts of the 7th Conference on Retrovirals and Opportunistic Infections. January 30th - February 2nd, 2000;San Francisco, CA, Abstract #580.
  26. Bruno RG, Howland MA, McMeeking AA, Hoffman RS.Long-acting Anticoagulant Overdose:Brodifacoum Kinetics and Optimal Vitamin K Dosing. Annals of Emergency Medicine.2000; 36:262-67.
Wohlfeiler M, Kessler HA, Ruane PJ, McMeeking, AA, et al.Improving Management and Optimizing Treatment for the HIV Positive Population.Monograph, Medimax Communications, December 2004: 1-23.